ARK shifts biotech bets: buys Prime Medicine, sells Absci stock

uk.investing.com —

Cathie Wood’s ARK Invest bought 1,744,714 shares of Prime Medicine for $6.8 million and sold 478,402 shares of Absci Corp for $4.8 million on Wednesday, November 11th, 2026. The Prime Medicine purchase was ARK’s largest trade of the day, executed through its ARKG ETF, while the Absci sale continues a recent trend of reducing that biotech holding. ARK also added 348,176 Archer Aviation shares and 85,203 Kratos Defense shares. ARK further trimmed positions in BYD, Honeywell Aerospace, and Teradyne, while making smaller buys in Rocket Lab and Scribe Therapeutics. The trades signal a strategic shift toward biotechnology and aerospace sectors.


With a significance score of 2, this news ranks in the top 23% of today's 31735 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: